Perspectives on Emerging Data and Best Practices for the Use of Novel Therapies in Endometrial Cancer: A Focused Update for Managed Care Pharmacists

Perspectives on Emerging Data and Best Practices for the Use of Novel Therapies in Endometrial Cancer: A Focused Update for Managed Care Pharmacists is organized by Pharmacy Times Continuing Education (PTCE).,Release date: May 18, 2022,Expiration date: May 18, 2023,Description:,Women with advanced or recurrent endometrial cancer experience poor prognosis and a 5-year survival rate of just 17%. Clinical efficacy and safety data supporting the use of immune checkpoint inhibitor-based therapies and combination therapy regimens have demonstrated increased benefit for patients with endometrial cancer, and current guidelines recommend treatment initiation with novel target-specific and immunotherapeutic approaches for patients with high-risk diseases. Managed care professionals can be instrumental in promoting the appropriate utilization of biomarker testing, helping to guide cost-effective treatment selection for patients with endometrial cancer. This activity will review recommendations on the use of biomarker testing in determining evidence-based treatment for patients whose disease has progressed despite therapy. Considerations for the management of immune-related toxicities as well as costs and strategies to treat these adverse effects will also be discussed.,Educational Objectives:,At the completion of this activity, participants will be able to:,• Demonstrate understanding of the epidemiology of endometrial cancer and the role of biomarkers in guiding treatment with novel therapies,• Determine the guideline-recommended role of molecularly targeted and immune-based therapies in the management of endometrial cancer,• Apply the evidence regarding the cost of care and cost-effectiveness of novel immunotherapy in the treatment of endometrial cancer